Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I/II bladder cancer trial shows 59% complete response rate on MCC therapy

June 26, 2001

Phase I/II trial begins for malignant melanoma vaccine

June 26, 2001

Second multicenter phase I/II trial of GVAX for NSCLC

June 22, 2001

Patient enrollment completed in phase III trial of CeaVac

June 21, 2001

MabThera monoclonal antibody approved in Japan

June 21, 2001

ImClone reaches second milestone in phase III evaluation of BEC2

June 19, 2001

Phase III comparative trial of PEG-Intron and Intron A for CML completed

June 14, 2001

Extension of pemtumomab phase III trial announced following meeting with FDA

June 12, 2001

Dendreon expands phase III trials of Provenge for prostate cancer

June 12, 2001

GM-CSF gene therapy for metastatic melanoma enters clinical testing

June 11, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...